Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYFORM-007
2024-511043-25-00Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in colorectal cancer (CRC) comparing MK-4280A with Standard of care (regorafenib or TAS-102) (2 arms). Primary endpoint: Overall Survival (OS). Started May 2024; status: completed.
02
Drugs
favezelimab + pembrolizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-511043-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511043-25-00.